Synergy Pharmaceuticals (FRA:S90) EV-to-EBIT : -0.58 (As of May. 17, 2024)

Synergy Pharmaceuticals EV-to-EBIT Chart

Synergy Pharmaceuticals Annual Data
	Trend	Dec08	Dec09	Dec10	Dec11	Dec12	Dec13	Dec14	Dec15	Dec16	Dec17
EV-to-EBIT		Get a 7-Day Free Trial					-6.94	-2.97	-6.78	-7.11	-2.16

Synergy Pharmaceuticals Quarterly Data
	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18
EV-to-EBIT	Get a 7-Day Free Trial															-2.55	-2.16	-2.17	-3.16	-3.64

Competitive Comparison of Synergy Pharmaceuticals's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Synergy Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Synergy Pharmaceuticals's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Synergy Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Synergy Pharmaceuticals's EV-to-EBIT falls into.

Synergy Pharmaceuticals EV-to-EBIT Calculation

Synergy Pharmaceuticals's EV-to-EBIT for today is calculated as:

Synergy Pharmaceuticals's current Enterprise Value is €65.50 Mil.
Synergy Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Sep. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was €-113.89 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Synergy Pharmaceuticals  (FRA:S90) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Synergy Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2018 is calculated as:

Synergy Pharmaceuticals's Enterprise Value for the quarter that ended in Sep. 2018 was €420.53 Mil.
Synergy Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Sep. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was €-113.89 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Synergy Pharmaceuticals EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Synergy Pharmaceuticals's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Synergy Pharmaceuticals (FRA:S90) Business Description